GWOXI Group

Gwoxi Stem Cell Applied Technology is a Taiwan-based biotechnology company specializing in the development of regenerative medicine and stem cell therapies. The company focuses on utilizing mesenchymal stem cells (MSCs) to treat chronic and degenerative diseases, including liver cirrhosis, osteoarthritis, and neurological disorders. Gwoxi operates a high-standard GMP cell production facility and has developed a proprietary platform for stem cell isolation and expansion. Their lead candidate, GXHPC1, is currently in clinical trials for liver cirrhosis, demonstrating their commitment to addressing unmet medical needs through advanced cell-based interventions. The company is publicly traded on the Taipei Exchange and maintains strong collaborations with leading medical institutions in Taiwan.